IATDMCT 2023
IATDMCT 2023: "Personalized under the Northern Sky"
21st Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology
24-27 September 2023
Oslo Congress Centre, Norway
https://gyroconference.eventsair.com/iatdmct/
Meet Shimadzu at IATDMCT
Shimadzu's technologies are used in the clinical environment both for daily routine analysis and for research and development of ultra-early diagnostics, diagnostics, medical treatments and prognostic phases. The axes of development are cancer, diseases related to lifestyle in order to be in better health for longer, as well as neurodegenerative diseases. With longstanding expertise in medical imaging as well as analytical instrumentation, Shimadzu is perfectly positioned to offer innovative and robust mass spectrometry-based solutions for therapeutic drug monitoring applications, toxicology studies, biomarker research and monitoring of new drugs based on monoclonal antibodies. Visit the Shimadzu booth at IATDMCT-2023 and chat with our experts to learn about all the solutions offered!
Workshop
"Fast & Selective TDM with Mass Spectrometry" | Monday 25th September
Speaker 1: Takashi SHIMADA, Shimadzu Corporation, Japan
Title: Streamlining a rapid and universal therapeutic antibody quantitation using Fab-selective proteolysis nSMOL-based multiplexed LC-MS/MS platform in clinical practice
Topic: nSMOL technology for mAbs analysis
Speaker 2: Pauline GRIFFEUILLE, CHU Limoges, France
Title: Probe Electrospray Ionization source coupled to Low- and High-resolution Mass Spectrometry: applications in TDM and clinical toxicology
Topic: PESI-MS/MS for quick screening & quantitation
Posters
24/7 fully automated therapeutic drug analysis for research projects by LC/MS/MS
Jaffuel A (1) , Streit F (2) , Fischer A (2)
(1) Shimadzu Corporation Japan, Kyoto, Japan
(2) Department of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany
Fully Automated LC-MS/MS Analysis of Aminoglycoside and Glycopeptide antibiotics
Kohei Yoshikawa (1), Toshikazu Minohata (1)
(1) Shimadzu Corporation Japan, Kyoto, Japan
Practical utility evaluation of a fully-automated method for quantifying 12 oral small molecules anticancer drugs
Reiko Ando Makihara (1,4), Yuki Katsuya (3) , Makoto Maeda (1), Daisuke Amenomiya (1), Kohei Yoshikawa (2), Eishi Imoto (2), Daisuke Kawakami (2), Yuki Kojima (4,7), Tatsuya Yoshida (3,5), Takafumi Koyama (3,7), Akiko Kubo (1), Daisuke Watabe (1), Yoshimasa Saito (1), Toru Akagi (1), Ken Kato (6,7), Noboru Yamamoto (3) and Hironobu Hashimoto (1)
(1) Department of Pharmacy, National Cancer Center Hospital
(2) SHIMADZU CORPORATION
(3) Department of Experimental Therapeutics, National Cancer Center Hospital
(4) Department of Medical Oncology, National Cancer Center Hospital
(5) Department of Thoracic Oncology, National Cancer Center Hospital
(6) Department of Head and Neck, Esophageal Medical Oncology / Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital
(7) Translational Research Specimen Control Section, National Cancer Center Hospital
Products
Please contact us during the conference to get more information.
Solutions
Databases / Library
